Levi & Korsinsky Alerts MoonLake Immunotherapeutics Investors of Class Action Lawsuit Deadline

Class Action Lawsuit Notification for MoonLake Investors

Levi & Korsinsky, LLP, a prominent law firm known for its focus on investor rights, has recently notified shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) regarding a class action securities lawsuit. This lawsuit is aimed at recovering losses for investors who faced an adverse impact due to alleged securities fraud committed by the company between March 10, 2024, and September 29, 2025.

Details of the Lawsuit

The class action complaint alleges that MoonLake made several misleading statements regarding its drug candidate, SLK, particularly in comparison to BIMZELX, another drug that operates on similar molecular targets. The key points of concern include:
1. Molecular Targets: Assertions that SLK's molecular structures and the structures of BIMZELX were deemed superior due to their distinct functionalities have been questioned.
2. Clinical Benefits: It is claimed that the unique structure of SLK may not provide any distinct clinical advantages over traditional monoclonal antibodies like BIMZELX.
3. Efficacy Claims: The lawsuit questions the company's implied efficacy promises based on SLK’s alleged ability to penetrate tissue more effectively. The implication is that these claims were made without sufficient evidence to back them up.
4. Investor Misrepresentation: Overall, the complaint argues that investors were misled about SLK’s potential benefits, which affected their investment decisions, ultimately leading to financial losses.

Important Dates and Next Steps

For investors who may have lost money while holding shares of MoonLake within the specified timeframe, the deadline to participate in the lawsuit is December 15, 2025. If you wish to be appointed as a lead plaintiff in this matter, it's vital to act quickly. However, note that participation does not require you to serve as a lead plaintiff.

No Upfront Costs

Participating in this class action comes at no cost to the investors. If you are recognized as a class member, you may still be entitled to compensation without any requirement to pay out-of-pocket costs or fees. This zero-cost approach lowers barriers for many investors potentially harmed by the company's actions.

Levi & Korsinsky: A Trusted Ally

Levi & Korsinsky has built a reputation over the past two decades as a reliable ally for aggrieved shareholders. With a history of securing hundreds of millions of dollars in settlements and judgments for its clients, the firm is recognized as a leader in the securities litigation space. Their consistent ranking in ISS Securities Class Action Services' Top 50 Report highlights their credibility and effectiveness in such matters.

Contact Information

Investors seeking more information can reach out to Joseph E. Levi, Esq., via email at email protected] or by calling (212) 363-7500. You can also visit [Levi & Korsinsky's website for further details about the lawsuit and how to get involved.

As the litigation unfolds, investors in MoonLake Immunotherapeutics are encouraged to remain vigilant and informed about their rights and options, especially given the implications of this lawsuit. It is essential to remain proactive, particularly if you believe you have been financially impacted during the specified period.